Recent Updates
Recently added Catalysts
WVE Neutral Sentiment Score: 55/100

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Key Takeaway: Wave Life Sciences Ltd. will conduct a live webcast and conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results, along with business updates. The event emphasizes the company's focus on RNA medicines to transform human health. Analysts can participate in the Q&A section during the call, and a recorded version will be available afterward. The company is committed to advancing its diverse pipeline, including programs for obesity, alpha-1 antitrypsin deficiency, and liver disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is focused on advancing RNA medicines, which has transformative potential.
  • The company is set to review its financial results and provide business updates.
  • Wave's innovative RNA medicines platform combines different modalities, offering significant scientific breakthroughs.

Full Press Release Details

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
VP, Corporate Affairs and Investor Relations
Director, Investor Relations
Senior Director, Corporate Communications

Frequently Asked Questions

When is Wave Life Sciences' financial results webcast?

The webcast is on February 26, 2026, at 8:30 a.m. ET.

How can I access the live conference call?

Visit the 'Investor Events' section on Wave Life Sciences' website.

What is Wave Life Sciences focused on?

They aim to unlock RNA medicines to transform human health.

What are some of Wave's pipeline programs?

Programs include WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency.

Where is Wave Life Sciences headquartered?

Wave Life Sciences is headquartered in Cambridge, Massachusetts.

Last updated: Feb 19, 2026